mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies
Objectives: Immunoglobulin (Ig) A antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection-prone patients with cancer. This might be par...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971225001638 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849249601668775936 |
|---|---|
| author | Yana Debie Lise Verbruggen Marc Peeters Peter A. van Dam Timon Vandamme |
| author_facet | Yana Debie Lise Verbruggen Marc Peeters Peter A. van Dam Timon Vandamme |
| author_sort | Yana Debie |
| collection | DOAJ |
| description | Objectives: Immunoglobulin (Ig) A antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection-prone patients with cancer. This might be particularly relevant for patients with cancer because they mount reduced IgG antibody titers after dual-dose BNT162b2 COVID-19 vaccination and even lower responses after double-dose ChAdOx1 vaccination than healthy individuals. However, data on vaccine-induced IgA antibodies are scarce, especially in patients with cancer. Methods: This study compares SARS-CoV-2 anti-spike (S1) IgA antibodies after dual-dose BNT162b2 vs ChAdOx1 vaccination in patients with cancer. SARS-CoV-2 anti-S1 IgA antibodies were quantified in serum samples collected 7 days after the second vaccination dose (N = 213) (IEQ-CoVS1RBD-IgA-1-RB enzyme-linked immunosorbent assay kit, RayBiotech) and analyzed with colorimetric detection. In addition, correlations with different aspects of humoral immunity were assessed (neutralizing and IgG antibodies). Results: Significantly lower anti-S1 IgA antibody titers were reported in patients with cancer after dual-dose ChAdOx1 than BNT162b2 vaccination. Moreover, patients with cancer who received dual-dose BNT162b2 vaccination had a significant 16.44-fold increased chance to mount detectable IgA antibodies compared with patients receiving ChAdOx1 vaccination. Conclusions: These findings highlight the potential role of boosters or alternative strategies to sustain mucosal immunity. |
| format | Article |
| id | doaj-art-1edfb95348124696aed2d70565f5127f |
| institution | Kabale University |
| issn | 1201-9712 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj-art-1edfb95348124696aed2d70565f5127f2025-08-20T03:57:31ZengElsevierInternational Journal of Infectious Diseases1201-97122025-09-0115810793910.1016/j.ijid.2025.107939mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategiesYana Debie0Lise Verbruggen1Marc Peeters2Peter A. van Dam3Timon Vandamme4Center for Oncological Research (CORE), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat, Edegem, BelgiumMultidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat, Edegem, BelgiumCenter for Oncological Research (CORE), University of Antwerp, Universiteitsplein 1, Wilrijk, BelgiumCenter for Oncological Research (CORE), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat, Edegem, BelgiumCenter for Oncological Research (CORE), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat, Edegem, Belgium; Corresponding author: (T. Vandamme); Tel.: +323 821 21 11.Objectives: Immunoglobulin (Ig) A antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection-prone patients with cancer. This might be particularly relevant for patients with cancer because they mount reduced IgG antibody titers after dual-dose BNT162b2 COVID-19 vaccination and even lower responses after double-dose ChAdOx1 vaccination than healthy individuals. However, data on vaccine-induced IgA antibodies are scarce, especially in patients with cancer. Methods: This study compares SARS-CoV-2 anti-spike (S1) IgA antibodies after dual-dose BNT162b2 vs ChAdOx1 vaccination in patients with cancer. SARS-CoV-2 anti-S1 IgA antibodies were quantified in serum samples collected 7 days after the second vaccination dose (N = 213) (IEQ-CoVS1RBD-IgA-1-RB enzyme-linked immunosorbent assay kit, RayBiotech) and analyzed with colorimetric detection. In addition, correlations with different aspects of humoral immunity were assessed (neutralizing and IgG antibodies). Results: Significantly lower anti-S1 IgA antibody titers were reported in patients with cancer after dual-dose ChAdOx1 than BNT162b2 vaccination. Moreover, patients with cancer who received dual-dose BNT162b2 vaccination had a significant 16.44-fold increased chance to mount detectable IgA antibodies compared with patients receiving ChAdOx1 vaccination. Conclusions: These findings highlight the potential role of boosters or alternative strategies to sustain mucosal immunity.http://www.sciencedirect.com/science/article/pii/S1201971225001638SARS-CoV-2COVID-19 vaccinationIgA antibodiesPatients with cancer |
| spellingShingle | Yana Debie Lise Verbruggen Marc Peeters Peter A. van Dam Timon Vandamme mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies International Journal of Infectious Diseases SARS-CoV-2 COVID-19 vaccination IgA antibodies Patients with cancer |
| title | mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies |
| title_full | mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies |
| title_fullStr | mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies |
| title_full_unstemmed | mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies |
| title_short | mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies |
| title_sort | mrna covid 19 vaccines induce superior immunoglobulin a titers in patients with cancer compared with viral vector vaccines implications for immunization strategies |
| topic | SARS-CoV-2 COVID-19 vaccination IgA antibodies Patients with cancer |
| url | http://www.sciencedirect.com/science/article/pii/S1201971225001638 |
| work_keys_str_mv | AT yanadebie mrnacovid19vaccinesinducesuperiorimmunoglobulinatitersinpatientswithcancercomparedwithviralvectorvaccinesimplicationsforimmunizationstrategies AT liseverbruggen mrnacovid19vaccinesinducesuperiorimmunoglobulinatitersinpatientswithcancercomparedwithviralvectorvaccinesimplicationsforimmunizationstrategies AT marcpeeters mrnacovid19vaccinesinducesuperiorimmunoglobulinatitersinpatientswithcancercomparedwithviralvectorvaccinesimplicationsforimmunizationstrategies AT peteravandam mrnacovid19vaccinesinducesuperiorimmunoglobulinatitersinpatientswithcancercomparedwithviralvectorvaccinesimplicationsforimmunizationstrategies AT timonvandamme mrnacovid19vaccinesinducesuperiorimmunoglobulinatitersinpatientswithcancercomparedwithviralvectorvaccinesimplicationsforimmunizationstrategies |